Research Radboud technology centers Radboud Biobank News Framework for accessing identifiable patient data
28 January 2021

A Framework for standards and assessment of accessing identifiable patient data for medical scientific research has been developed in the Radboudumc. This has been translated into a Standard Operating Procedure (SOP) found in the Quality Systems Scientific Human Research. This SOP describes how to use research functionalities in Epic to record research activities in patients and healthy volunteers. It further describes the Epic authorization process for Radboudumc employees (with or without direct patient care), students, internal/external monitors, and external researchers.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more